Skip to main content

Table 1 Characteristics of 2888 patients in the Chicago multiethnic epidemiologic cohort of breast cancer study*

From: Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients

Characteristic White Black Asian Hispanic P
N 1575 1106 126 81  
Age at diagnosis, n (%)
 < 40 147 (9.3) 86 (7.8) 17 (13.5) 15 (18.5) < 0.001
 40–49 432 (27.4) 191 (17.3) 48 (38.1) 23 (28.4)  
 -59 463 (29.4) 262 (23.7) 25 (19.8) 14 (17.3)  
 60–69 334 (21.2) 262 (23.7) 25 (19.8) 15 (18.5)  
 70+ 199 (12.6) 305 (27.6) 11 (8.7) 14 (17.3)  
Mean (SD) 54.7 (12.3) 59.6 (13.9) 51.1 (12.5) 53.8 (14.5) < 0.001
Smoking status, n (%)
 Never smoker 968 (63.5) 597 (55.2) 105 (90.5) 48 (62.3) < 0.001
 Previous smoker 416 (27.3) 313 (29.0) 9 (7.8) 23 (29.9)  
 Current smoker 140 (9.2) 171 (15.8) 2 (1.7) 6 (7.8)  
Insurance status, n (%)
 No 7 (0.4) 2 (0.2) 0 (0.0) 1 (1.2) < 0.001
 Private 1149 (73.0) 433 (39.2) 95 (75.4) 52 (64.2)  
 Medicaid 37 (2.3) 166 (15.0) 4 (3.2) 5 (6.2)  
 Medicare 346 (22.0) 476 (43.0) 25 (19.8) 22 (27.2)  
 Other/unknown 36 (2.3) 29 (2.6) 2 (1.6) 1 (1.2)  
Carlson comorbidity index, n (%)
 0 1318 (83.7) 762 (68.9) 108 (85.7) 63 (77.8) < 0.001
 1 114 (7.2) 134 (12.1) 11 (8.7) 6 (7.4)  
 2 115 (7.3) 132 (11.9) 4 (3.2) 11 (13.6)  
 3 28 (1.8) 78 (7.1) 3 (2.4) 1 (1.2)  
Tumor stage, n (%)
 0 263 (16.7) 195 (17.6) 24 (19.0) 9 (11.1) 0.097
 1 628 (39.9) 372 (33.6) 42 (33.3) 30 (37.0)  
 2 505 (32.1) 391 (35.4) 43 (34.1) 30 (37.0)  
 3 179 (11.4) 148 (13.4) 17 (13.5) 12 (14.8)  
Estrogen receptor, n (%)
 Negative 284 (19.2) 307 (30.3) 16 (13.6) 20 (25.3) < 0.001
 Positive 1193 (80.8) 706 (69.7) 102 (86.4) 59 (74.7)  
Progesterone receptor, n (%)
 Negative 458 (31.1) 436 (43.0) 29 (24.6) 26 (32.9) < 0.001
 Positive 1016 (68.9) 578 (57.0) 89 (75.4) 53 (67.1)  
Her2 status, n (%)
 Negative 1051 (83.7) 734 (83.1) 76 (74.5) 62 (87.3) 0.084
 Positive 204 (16.3) 149 (16.9) 26 (25.5) 9 (12.7)  
Molecular subtype, n (%)
 ER/PR+, her2- 884 (70.4) 511 (57.9) 68 (66.7) 49 (69.0) < 0.001
 ER/PR+, her2+ 128 (10.2) 90 (10.2) 18 (17.6) 6 (8.5)  
 ER/PR-, her2+ 76 (6.1) 58 (6.6) 8 (7.8) 3 (4.2)  
 Triple negative 167 (13.3) 223 (25.3) 8 (7.8) 13 (18.3)  
Histologic grade, n (%)
 1 230 (15.6) 134 (12.8) 21 (17.8) 9 (11.5) < 0.001
 2 742 (50.3) 456 (43.6) 61 (51.7) 41 (52.6)  
 3 504 (34.1) 456 (43.6) 36 (30.5) 28 (35.9)  
Type of surgery, n (%)
 No surgery 13 (0.8) 12 (1.1) 0 (0.0) 0 (0.0) < 0.001
 Breast conserving surgery 913 (58.7) 683 (65.1) 62 (49.6) 45 (57.7)  
 Mastectomy 629 (40.5) 354 (33.8) 63 (50.4) 33 (42.3)  
Chemotherapy, n (%)
 No 881 (55.9) 586 (53.0) 71 (56.3) 39 (48.1) 0.28
 Yes 694 (44.1) 520 (47.0) 55 (43.7) 42 (51.9)  
Hormonal therapy, n (%)
 No 495 (31.4) 462 (41.8) 27 (21.4) 28 (34.6) < 0.001
 Yes 1080 (68.6) 644 (58.2) 99 (78.6) 53 (65.4)  
Radiotherapy, n (%)
 No 657 (41.7) 437 (39.5) 63 (50.0) 28 (34.6) 0.074
 Yes 918 (58.3) 669 (60.5) 63 (50.0) 53 (65.4)  
BMI at baseline, n (%)
 Underweight 19 (1.4) 4 (0.5) 2 (2.0) 0 (0.0) < 0.001
 Normal weight 548 (41.6) 143 (16.9) 58 (58.6) 13 (22.4)  
 Overweight 388 (29.5) 261 (30.9) 28 (28.3) 30 (51.7)  
 Obese 362 (27.5) 438 (51.8) 11 (11.1) 15 (25.9)  
Mean (SD) 27.5 (6.4) 31.5 (7.3) 24.6 (4.3) 28.7 (6.2) < 0.001
  1. *Number (%) are presented if not otherwise specified and numbers are not added up to total due to missing data. In particular, Her2 data were collected for few patients with stage 0 tumors
  2. Abbreviation: BMI body mass index, SD standard deviation, ER estrogen receptor, PR progesterone receptor